The Vanderbilt Center for Neuroscience Drug Discovery Announces New Drug Candidates for Schizophrenia Entering Preparation for First-in-Human Clinical Testing
Monday, December 12, 2011 - 11:31
in Health & Medicine
The Vanderbilt Center for Neuroscience Drug Discovery announced today that new drug candidates for schizophrenia generated from its ongoing collaboration with Janssen Pharmaceutica, NV, are now entering the stage of preparation for first-in-human clinical testing. "This is a major step forward in the evaluation of this approach as a potential treatment for major psychiatric diseases. It could lead to a fundamental advance in the treatment of schizophrenia," said P. Jeffrey Conn, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery .